LOTEMAX SM Drug Patent Profile
✉ Email this page to a colleague
When do Lotemax Sm patents expire, and what generic alternatives are available?
Lotemax Sm is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has thirty patent family members in thirteen countries.
The generic ingredient in LOTEMAX SM is loteprednol etabonate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lotemax Sm
A generic version of LOTEMAX SM was approved as loteprednol etabonate by SENTISS on April 17th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LOTEMAX SM?
- What are the global sales for LOTEMAX SM?
- What is Average Wholesale Price for LOTEMAX SM?
Summary for LOTEMAX SM
International Patents: | 30 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 22 |
Drug Prices: | Drug price information for LOTEMAX SM |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LOTEMAX SM |
What excipients (inactive ingredients) are in LOTEMAX SM? | LOTEMAX SM excipients list |
DailyMed Link: | LOTEMAX SM at DailyMed |
Recent Clinical Trials for LOTEMAX SM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Thomas Chester, OD | Phase 4 |
Illinois College of Optometry | Early Phase 1 |
Shiraz University of Medical Sciences | Phase 4 |
Pharmacology for LOTEMAX SM
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Paragraph IV (Patent) Challenges for LOTEMAX SM
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LOTEMAX SM | Ophthalmic Gel | loteprednol etabonate | 0.38% | 208219 | 1 | 2022-11-14 |
US Patents and Regulatory Information for LOTEMAX SM
LOTEMAX SM is protected by two US patents.
Patents protecting LOTEMAX SM
Ophthalmic suspension composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | LOTEMAX SM | loteprednol etabonate | GEL;OPHTHALMIC | 208219-001 | Feb 22, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Bausch And Lomb Inc | LOTEMAX SM | loteprednol etabonate | GEL;OPHTHALMIC | 208219-001 | Feb 22, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LOTEMAX SM
See the table below for patents covering LOTEMAX SM around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20170105610 | 안과용 현탁액 조성물 | ⤷ Sign Up |
South Korea | 102538370 | ⤷ Sign Up | |
Japan | 2018507252 | 眼用懸濁組成物 | ⤷ Sign Up |
European Patent Office | 4268850 | COMPOSITION DE SUSPENSION OPHTALMIQUE (OPHTHALMIC SUSPENSION COMPOSITION) | ⤷ Sign Up |
Australia | 2023248145 | Ophthalmic suspension composition | ⤷ Sign Up |
European Patent Office | 4082531 | COMPOSITION DE SUSPENSION OPHTALMIQUE (OPHTHALMIC SUSPENSION COMPOSITION) | ⤷ Sign Up |
Mexico | 2017009699 | COMPOSICION DE SUSPENSION OFTALMICA. (OPHTHALMIC SUSPENSION COMPOSITION.) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |